What are the most commonly reported adverse reactions to Dectova zanamivir hydrate?

In adults receiving 600 mg intravenously twice daily in Phase II/III studies, the most commonly reported reactions considered possibly or probably related to Dectova (zanamivir hydrate) were increased alanine aminotransferase (2%), increased aspartate aminotransferase (1%), hepatocellular injury (1%), diarrhoea (1%) and rash (1%).